CXL Ophthalmics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- September 30, 2022
- Vertical
- Healthcare
- Funding URL
- View Funding Page
- Funding Amount:
- $32,000,000
Company Info
- Company Description
- CXL Ophthalmics is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Their EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.
- Market
- Ophthalmology
- Location
- Sherborn, MA, USA
- Coinvestors
- AXA IM Alts